Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P403 Post hoc examination of VISIBLE 1 data for baseline predictors of response to 2 or 3 IV doses of vedolizumab for adults with moderate-to-severe ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

W. Sandborn1, E.V. Loftus Jr2, F. Baert3, J. Jansson4, J. Chen4, N. Candela5, K. Lasch5, K. Kisfalvi4

1Division of Gastroenterology, University of California San Diego, La Jolla, USA, 2Gastroenterology, Mayo Clinic, Rochester, USA, 3Department of Gastroenterology and Hepatology, AZ Delta, Roeselare, Belgium, 4Gastroenterology, Takeda Development Center Americas Inc., Cambridge, USA, 5Gastroenterology, US Medical Office- Takeda Pharmaceuticals U.S.A.- Inc., Deerfield, USA

P404 Prolonged steroid exposure prior to admission is associated with increased likelihood of rescue therapy and colectomy in acute severe ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

A. Barnes1,2, P. Spizzo1

1Gastroenterology, Flinders Medical Centre, Adelaide, Australia, 2College of Medicine and Public Health, Flinders University, Adelaide, Australia

P405 Comparison of long-term outcomes of infliximab vs. adalimumab in 1488 biologic-naive Korean patients with Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

Y.S. Jung Prof. Dr.1, M. Han2, S. Park3, J.H. Cheon4

1Internal Medicine, Kangbuk Samsung Hospital, Seoul, Republic of Korea, 2Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea, 3Biostatistics, Yonsei University, Seoul, Republic of Korea, 4Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea

P406 Adherence, acceptability and serum trough concentration of adalimumab autoinjector in quiescent patients with inflammatory bowel diseases

ECCO'20 Vienna

Year: 2020
Authors:

S. Kato, N. Yamaga, A. Ishibashi, K. Kani, S. Nagoshi

Department of Gastroenterology and Hepatology, Saitama Medical Centre- Saitama Medical University, Kawagoe City, Saitama, Japan

P407 Is the rapid infliximab infusion a safe and cost-saving strategy in paediatric inflammatory bowel disease?

ECCO'20 Vienna

Year: 2020
Authors:

G. Pujol Muncunill1, J. Martínez-Osorio1, F. Bossacoma-Busquets2, L. Álvarez-Carnero1, J. Arrojo-Juárez2, V. Vila-Miravet1, F.J. Martin De Carpi1

1Department of Pediatric Gastroenterology- Hepatology and Nutrition, Hospital Sant Joan de Déu, Unit for the Comprehensive Care of Pediatric Inflammatory Bowel Disease, Esplugues del Llobregat, Spain, 2Pharmacy Department, Hospital Sant Joan de Déu, Esplugues del Llobregat, Spain

P408 Long-term impact of the decrease of infliximab trough levels on the disease course in Inflammatory Bowel Disease patients under maintenance treatment with infliximab

ECCO'20 Vienna

Year: 2020
Authors:

E. Orfanoudaki1, M. Gazouli2, K. Foteinogiannopoulou1, E. Theodoraki1, E. Legaki2, I. Koutroubakis1

1Gastroenterology, University Hospital of Heraklion, Heraklion Crete, Greece, 2Laboratory of Biology- Department of Basic Medical Science, National and Kapodistrian University of Athens, Athens, Greece

P409 Endoscopic and histological activity is associated with non-response to biologic therapy in ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

S. WANN1, R. Norris1, R. Williams2, C. Basnayake1, M. Lust1, E. Wright1, M. Kamm1, W. Connell1, A. Thompson1, N. Ding1

1Gastroenterology, St Vincent’s Hospital Melbourne, Melbourne, Australia, 2Anatomical Pathology, St Vincent’s Hospital Melbourne, Melbourne, Australia

P410 Could the disease become ‘a friend’? The mediating role of illness acceptance on self-efficacy and quality of life of gastroenterological patients

ECCO'20 Vienna

Year: 2020
Authors:

A. Rudnik1,2, G. Piotrowicz2, G. Rydzewska3,4, M. Bidzan1, E. Ozgo5

1Institute of Psychology, University of Gdansk, Gdańsk, Poland, 2Department of Gastroenterology, Clinical Hospital of the Ministry of the Interior and Administration in Gdansk, Gdansk, Poland, 3Department of Internal Medicine and Gastroenterology with Inflammatory Bowel Disease Subdivision, Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw, Warsaw, Poland, 4Department of the Prevention of Alimentary Tract Diseases- Faculty of Medicine and Health Science, Jan Kochanowski University, Kielce, Poland, 5Division of Psychiatry, University College London, London, UK

P411 Faecal calprotectin is more tightly associated with endoscopic disease activity compared with other biomarkers in patients with inflammatory bowel disease under maintenance treatment with adalimumab

ECCO'20 Vienna

Year: 2020
Authors:

E. Orfanoudaki, E. Theodoraki, K. Foteinogianopoulou, A. Mantaka, I. Koutroubakis

Gastroenterology, University Hospital of Heraklion, Heraklion Crete, Greece

P412 Maintenance therapy of vedolizumab (VDZ) after induction of remission by tacrolimus (TAC) in patients with refractory ulcerative colitis (UC)

ECCO'20 Vienna

Year: 2020
Authors:

A. Ito, M. Shun, O. Teppei, T. Katsutoshi

Department of Gastroenterology- Department of Medicine, Tokyo Women’s Medical University Hospital, Tokyo, Japan

P413 General impressions about nutrition in patients with inflammatory bowel disease using a nutritional survey

ECCO'20 Vienna

Year: 2020
Authors:

M.A. Ruiz-Ramirez1, C. Suarez1, J. Poza1, E. Martin-Arranz1, J.L. Rueda-Garcia1, M. Sanchez-Azofra1, M. Cuadros1, P. Mayor1, L. Garcia-Ramirez2, M.D. Martin-Arranz1

1Gastroenterology, Hospital Universitario La Paz, Madrid, Spain, 2Clinical Trials, Hospital Universitario La Paz, Madrid, Spain

P414 Risk factors for the development of anti-drug antibodies to infliximab and adalimumab in Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

E. Khoo1, A. Lord2, K. Hanigan1, A. Croft1, G. Radford-Smith1,2

1Royal Gastroenterology Department, Brisbane and Women’s Hospital, Herston, Australia, 2QIMR Berghofer Medical Research Institute, Gut Health Laboratory, Herston, Australia

P415 The anti-IL-23/IL-12 agent Ustekinumab is an effective and safe induction therapy in patients with Crohn’s disease refractory or intolerant to anti-TNF: a multicentre Italian study

ECCO'20 Vienna

Year: 2020
Authors:

A. Gubbiotti1, B. Barberio1, F. Zingone1, R. D’Incà1, L. Bertani2, A. Ferronato3, M.T. Urbano4, R. Sablich4, E.V. Savarino1

1Department of Surgery- Oncology and Gastroenterology, University of Padua, Padua, Italy, 2Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, 3ULSS7 Pedemontana- Santorso VI, Digestive Endoscopy Unit, Santorso, Italy, 4Gastroenterology Unit, Santa Maria Degli Angeli Hospital- Pordenone, Pordenone, Italy

P416 Results of the first paediatric randomised controlled trial of faecal microbiota transplant for ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

N. Pai2, J. Popov3, L. Hill4, E. Hartung1, K. Grzywacz5, D. Godin5, L. Thabane6, C. Lee7, W. Khan7, M. Surette2,8,9, P. Moayyedi2,8

1McMaster Paediatric FMT Research Program, 1Division of Gastroenterology and Nutrition- McMaster Children’s Hospital, Paediatrics, Hamilton, Canada, 2Farncombe Family Digestive Health Research Institute, Department of Medicine- McMaster University, Hamilton, Canada, 3College of Medicine and Health, University College Cork, Cork, Ireland, 4Department of Exercise Science and Sports Medicine, University of Cape Town, Cape Town, South Africa, 5Division de Gastroentérologie- Hépatologie et Nutrition- Université de Montréal, Département de Pédiatrie, Montreal, Canada, 6Department of Health Research Methods- Evidence- and Impact, McMaster University, Hamilton, Canada, 7Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Canada, 8Department of Medicine, Division of Gastroenterology and Hepatology- McMaster University, Hamilton, Canada, 9Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Canada

P417 Do ACE inhibitors and angiotensin II receptor blockers improve disease outcomes in inflammatory bowel disease?

ECCO'20 Vienna

Year: 2020
Authors:

K. FAIRBRASS1, D. Hoshen1, A.C. Ford1,2, D. Gracie1

1Leeds Gastroenterology Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK, 2Leeds Institute of Medical Research at St. James’s, University of Leeds, Leeds, UK

P418 Filgotinib decreases molecular markers of JAK1 signal transduction in Crohn’s disease: concordance with endoscopy and histopathology

ECCO'20 Vienna

Year: 2020
Authors:

W. Reinisch1, J. Brodbeck2, R. Galien3, E. Grant2, X. Hébuterne4, M. Kłopocka5, R. Petryka6, X. Roblin7, A. Serone2, C. Tasset8, O.K. Yoon2, S. Zaboli2, S. Vermeire9

1Division Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria, 2Gilead Sciences, Inc., Foster City, USA, 3Galapagos SASU, Parc Biocitech, Romainville, France, 4Department of Gastroenterology and Nutrition and Archet 2 Hospital, Centre Hospitalier Universitaire de Nice and University Côte d’Azur Nice, France, 5NC Department of Gastroenterology and Nutrition, University in Toruñ and Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland, 6NZOZ ViVamed, Zamiejska 17 03-580, Warsaw, Poland, 7Department of Gastroenterology, University Hospital of Saint Etienne, Saint Etienne, France, 8Galapagos NV, Generaal De Wittelaan L11A3, Mechelen, Belgium, 9Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium

P419 Clinical effectiveness and safety of first-line biologic vedolizumab as a monotherapy or combination therapy in ulcerative colitis and Crohn’s disease patients: results from the EVOLVE study

ECCO'20 Vienna

Year: 2020
Authors:

B. Bressler1, A. Yarur2, U. Kopylov3, M. Bassel4, N. Brett4, C. Colby5, C. Lopez6, S. Saha7, C. Kifnidi8, C. Agboton9, S. Adsul9, D. Demuth10, M. Luo11, S. Wang11, G.J. Mantzaris12

1Gastroenterology, St. Paul’s Hospital, Vancouver, Canada, 2Gastroenterology, Medical College of Wisconsin, Milwaukee, USA, 3Gastroenterology, Sheba Medical Center, Tel Aviv, Israel, 4Evidera, Real-World Evidence, Montreal, Canada, 5Evidera, Real-World Evidence, San Francisco, USA, 6Takeda Pharmaceuticals USA Inc., Medical Affairs, Deerfield, USA, 7Takeda Canada Inc., Medical Affairs, Oakville, Canada, 8Takeda Hellas S.A, Medical Affairs, Athens, Greece, 9Takeda Pharmaceuticals International AG, Global Medical Affairs, Zurich, Switzerland, 10Takeda Pharmaceuticals International, Evidence Generation and Publications, Singapore, Singapore, 11Takeda Pharmaceuticals International, Global Outcomes Research, Boston, USA, 12Evangelismos Hospital, Gastroenterology, Athens, Greece

P420 A randomised, observer-blinded phase Ib multiple, ascending dose study of UTTR1147A, an IL-22Fc fusion protein, in healthy volunteers and ulcerative colitis patients

ECCO'20 Vienna

Year: 2020
Authors:

F. Wagner1, J. Mansfield2, C. Geier1, A. Dash3, Y. Wang3, C. Li3, A. Lekkerkerker3, T. Lu3

1Charité Research Organisation, Charité – Universitätsmedizin Berlin, Berlin, Germany, 2Gastroenterology, Newcastle Upon Tyne Hospitals, Newcastle upon Tyne, UK, 3Genentech, Research and Early Development, South San Francisco, USA

P421 Prognostic and therapeutic long-term outcome of patients with ulcerative proctitis: analysis from a large referral centre cohort study

ECCO'20 Vienna

Year: 2020
Authors:

E. Dubois, A. Moens, J. Sabino, M. Ferrante, S. Vermeire

Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium

P422 Tofacitinib induces clinical and endoscopic remission in biologic refractory ulcerative colitis patients: a real-world Belgian cohort study

ECCO'20 Vienna

Year: 2020
Authors:

A. Cremer1, T. Lobaton2, S. Vieujan3, P. Bossuyt4, J.F. Rahier5, F. Baert6, O. Dewit7, M. Somers8, E. Macken8, A. Vijverman9, P. Van Hootegem10, F. Mana11, B. Willandt12, P. Caenepeel13, E. Humblet13, F. D’Heygere14, A. Verreth15, A. El Nawar16, J.L. Coenegrachts17, S. Dewit18, S. De Coninck19, N. Schoofs20, S. Delen21, J. Dutre22, C. Thienpont23, S. Vanden Branden24, D. Staessen25, D. Franchimont1, Belgian Inflammatory Bowel Disease Research and Development (BIRD) Group

1Department of Gastroenterology, Erasme University Hospital- ULB, Brussels, Belgium, 2Department of Gastroenterology, University Hospital Ghent, Ghent, Belgium, 3Department of Gastroenterology, CHU Sart Tilman, Liège, Belgium, 4Department of Gastroenterology, Imelda General Hospital, Bonheiden, Belgium, 5Department of Gastroenterology, CHU UCL Namur, Yvoir, Belgium, 6Department of Gastroenterology, AZ Delta, Roeselare, Belgium, 7Department of Gastroenterology, Clin Univ Saint Luc, Brussels, Belgium, 8Department of Gastroenterology, University Hospital Antwerp, Edegem, Belgium, 9Department of Gastroenterology, CHR de la Citadelle, Liège, Belgium, 10Department of Gastroenterology, AZ Sint-Lucas, Brugge, Belgium, 11Department of Gastroenterology, Clinique Saint-Jean, Brussels, Belgium, 12Department of Gastroenterology, AZ Sint-Jan, Brugge, Belgium, 13Department of Gastroenterology, Ziekenhuis Oost-Limburg Sint-Jan, Genk, Belgium, 14Department of Gastroenterology, AZ Groeninge, Kortrijk, Belgium, 15Department of Gastroenterology, AZ Sint-Jozef, Malle, Belgium, 16Department of Gastroenterology, CH Mouscron, Mouscron, Belgium, 17Department of Gastroenterology, Jessa ZH, Hasselt, Belgium, 18Department of Gastroenterology, Maria ZH Noord-Limburg, Overpelt, Belgium, 19Department of Gastroenterology, Sint-Andries ZH, Tielt, Belgium, 20Department of Gastroenterology, Sint-Trudo ZH, Sint-Truiden, Belgium, 21Department of Gastroenterology-, ZH Maas en Kempen, Maaseik, Belgium, 22Department of Gastroenterology, ZNA Jan Palfijn, Merksem, Belgium, 23Department of Gastroenterology, ZNA Antwerpen, Antwerpen, Belgium, 24Department of Gastroenterology, Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium, 25Department of Gastroenterology, GZA Sint-Vincentius ZH, Antwerpen, Belgium